NovaBridge Biosciences (NBP) Construction in Progress (2021 - 2022)
NovaBridge Biosciences (NBP) posted quarterly Construction in Progress of $874276.2 for Q4 2022, down 73.51% year-over-year from $3.3 million in Q4 2021, and down 4.24% quarter-over-quarter from $913000.0 in Q2 2022.
Powered by 
Analysis
NovaBridge Biosciences (NBP) Construction in Progress (2021 - 2022) Analysis & Trends
NovaBridge Biosciences (NBP) has reported Construction in Progress for 2 consecutive years, with $874276.2 the latest figure, recorded in Q4 2022.
- In Q4 2022, Construction in Progress fell 73.51% year-over-year to $874276.2; the TTM figure through Dec 2022 stood at $874276.2 (down 73.51% YoY), while the FY2022 annual figure was $901000.0, down 72.7% from the prior year.
- Construction in Progress slipped to $874276.2 in Q4 2022 per NBP's latest filing, from $913000.0 in the prior quarter.
- Across five years, Construction in Progress topped out at $139.9 million in Q2 2021 and bottomed at $874276.2 in Q4 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 152.67 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | NovaBridge Biosciences | 197.68 Mn | 197.68 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 874,276.16 |
| Jun 30, 2022 | 913,000.00 |
| Dec 31, 2021 | 3.30 Mn |
| Jun 30, 2021 | 139,899.18 |